Report Summarizes Glioblastomas Study Findings from College of Medicine [Clinical Benefit of Bevacizumab and Irinotecan (Bev Plus Iri) In Patients With Relapsed/refractory Glioblastoma (R/rgbm) and Its Potential Predictors]

  • Seok Lee

Press/Media

Period8 Mar 2023

Media coverage

1

Media coverage

  • TitleReport Summarizes Glioblastomas Study Findings from College of Medicine [Clinical Benefit of Bevacizumab and Irinotecan (Bev Plus Iri) In Patients With Relapsed/refractory Glioblastoma (R/rgbm) and Its Potential Predictors]
    Media name/outletImmunotherapy Daily
    Country/TerritoryUnited States
    Date8/03/23
    PersonsSeok Lee
View all 1
View less